Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation

Meng Sha, Jun Wang, Jie Cao, Zhi-Hui Zou, Xiao-ye Qu, Zhi-feng Xi, Chuan Shen, Ying Tong, Jian-jun Zhang, Seogsong Jeong, Qiang Xia

Clin Mol Hepatol. 2025;31(Suppl):S285-S300. Published online August 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0323

View: 1714 Download: 171 Crossref: 1

Liquid biopsy in hepatocellular carcinoma: Challenges, advances, and clinical implications

Jaeho Park, Yi-Te Lee, Vatche G. Agopian, Jessica S Liu, Ekaterina K. Koltsova, Sungyong You, Yazhen Zhu, Hsian-Rong Tseng, Ju Dong Yang

Clin Mol Hepatol. 2025;31(Suppl):S255-S284. Published online November 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0541

View: 1656 Download: 182

Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang

Clin Mol Hepatol. 2025;31(Suppl):S228-S254. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0824

View: 4018 Download: 647 Crossref: 3

Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2025;31(Suppl):S182-S195. Published online November 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0837

View: 1649 Download: 153 Crossref: 1

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2025;31(Suppl):S51-S75. Published online June 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0246

View: 6008 Download: 220 Crossref: 3

Reply to Correspondence

Reply to correspondence on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”

Hyuk Soo Eun

Clin Mol Hepatol. 2025;31(2):e215-e217. Published online January 16, 2025

DOI: https://doi.org/10.3350/cmh.2025.0035

View: 490 Download: 19

Correspondence

Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Seogsong Jeong, Won Kim, Sang Min Park

Clin Mol Hepatol. 2025;31(2):e208-e209. Published online January 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1171

View: 720 Download: 20

Correspondence to editorial on “Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma”

Kwang-Woong Lee, Young-Joon Kim

Clin Mol Hepatol. 2025;31(2):e206-e207. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0164

View: 357 Download: 17

Correspondence to editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”

Weifeng Zeng, Furong Liu, Yachong Liu, Zhanguo Zhang

Clin Mol Hepatol. 2025;31(2):e197-e199. Published online February 5, 2025

DOI: https://doi.org/10.3350/cmh.2025.0085

View: 419 Download: 23

Correspondence to editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”

Rong-Qi Sun, Shao-Lai Zhou

Clin Mol Hepatol. 2025;31(2):e192-e193. Published online February 26, 2025

DOI: https://doi.org/10.3350/cmh.2025.0183

View: 331 Download: 18

Correspondence to editorial on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”

Yang Liu, Fan Peng, Siyuan Wang, Jinliang Xing

Clin Mol Hepatol. 2025;31(2):e166-e168. Published online January 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1185

View: 454 Download: 25 Crossref: 1

Letter to the Editor

Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Hai Xu, Yong Zhou, Huikun Wu

Clin Mol Hepatol. 2025;31(2):e125-e127. Published online December 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.1087

View: 639 Download: 20

Editorial

Screening of patients at high risk of de novo recurrence in HCC: Editorial on “Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma”

Ping Huang, Shiqiao Luo, Rui Liao

Clin Mol Hepatol. 2025;31(2):662-664. Published online February 11, 2025

DOI: https://doi.org/10.3350/cmh.2025.0106

View: 359 Download: 25

TM4SF1 - A new immune target for treatment of hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”

Chen Rui Yuan, Terence Kin Wah Lee

Clin Mol Hepatol. 2025;31(2):646-649. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0102

View: 426 Download: 33

Genetic insights into sarcomatoid hepatocellular carcinoma: Critical role of ARID2 in pathogenesis and immune feature: Editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”

Naoshi Nishida

Clin Mol Hepatol. 2025;31(2):635-639. Published online January 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0071

View: 402 Download: 24

Circulating cell-free mitochondrial DNA for diagnosing hepatocellular carcinoma and assessing prognosis: Editorial on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”

Hyuk soo Eun

Clin Mol Hepatol. 2025;31(2):599-602. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1133

View: 565 Download: 37 Crossref: 2

Original Article

Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma

Da-Won Kim, Jin Hyun Park, Suk Kyun Hong, Min-Hyeok Jung, Ji-One Pyeon, Jin-Young Lee, Kyung-Suk Suh, Nam-Joon Yi, YoungRok Choi, Kwang-Woong Lee, Young-Joon Kim

Clin Mol Hepatol. 2025;31(2):563-576. Published online January 13, 2025

DOI: https://doi.org/10.3350/cmh.2024.0899

View: 681 Download: 60

Male preference for TERT alterations and HBV integration in young-age HBV-related HCC: implications for sex disparity

Jin Seoub Kim, Hye Seon Kim, Kwon Yong Tak, Ji Won Han, Heechul Nam, Pil Soo Sung, Sung Won Lee, Jung Hyun Kwon, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang

Clin Mol Hepatol. 2025;31(2):509-524. Published online January 2, 2025

DOI: https://doi.org/10.3350/cmh.2024.0545

View: 1026 Download: 104

Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma

Weifeng Zeng, Furong Liu, Yachong Liu, Ze Zhang, Haofan Hu, Shangwu Ning, Hongwei Zhang, Xiaoping Chen, Zhibin Liao, Zhanguo Zhang

Clin Mol Hepatol. 2025;31(2):489-508. Published online December 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0934

View: 1772 Download: 269 Crossref: 5

Integrated molecular characterization of sarcomatoid hepatocellular carcinoma

Rong-Qi Sun, Yu-Hang Ye, Ye Xu, Bo Wang, Si-Yuan Pan, Ning Li, Long Chen, Jing-Yue Pan, Zhi-Qiang Hu, Jia Fan, Zheng-Jun Zhou, Jian Zhou, Cheng-Li Song, Shao-Lai Zhou

Clin Mol Hepatol. 2025;31(2):426-444. Published online December 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0686

View: 1315 Download: 137

Reply to Correspondence

Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Hiroaki Kanzaki, Yujin Hoshida

Clin Mol Hepatol. 2025;31(1):e121-e122. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0886

View: 919 Download: 35

Reply to correspondence on “UBE2S: A novel driver of HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma”

Martina Mang Leng Lei, Terence Kin Wah Lee

Clin Mol Hepatol. 2025;31(1):e119-e120. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0621

View: 879 Download: 34

Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”

Mirko Zoncapè, Emmanuel A. Tsochatzis

Clin Mol Hepatol. 2025;31(1):e117-e118. Published online November 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0994

View: 755 Download: 19

Reply to correspondence on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”

Antonio Bertoletti, Anthony T Tan

Clin Mol Hepatol. 2025;31(1):e113-e116. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0867

View: 1018 Download: 31

Correspondence

Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Peng Wei, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e110-e112. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0828

View: 955 Download: 48

Correspondence to letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”

Gi-Ae Kim, Seung Won Choi, Young-Suk Lim

Clin Mol Hepatol. 2025;31(1):e108-e109. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0619

View: 964 Download: 32

Correspondence to letter to the editor 2 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”

Chun-Ting Ho, Elise Chia-Hui Tan, Chien-Wei Su

Clin Mol Hepatol. 2025;31(1):e101-e102. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0946

View: 652 Download: 14

Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”

Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim

Clin Mol Hepatol. 2025;31(1):e98-e100. Published online October 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0916

View: 829 Download: 47

Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”

Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e81-e83. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0829

View: 929 Download: 34 Crossref: 1

Correspondence to editorial on “UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL”

Renyu Zhang, Ding Wei, Zhinan Chen, Huijie Bian

Clin Mol Hepatol. 2025;31(1):e58-e60. Published online July 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0590

View: 945 Download: 56 Crossref: 1

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next

Viewed By 8476	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7412	MAFLD: How is it different from NAFLD?
Viewed By 5376	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5004	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4547	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 319	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 291	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 186	MAFLD: How is it different from NAFLD?
Cited By 101	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 92	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search